For in vitro diagnostic use. Others cobas Zika Test 5800 6800 8800 IVD cobas® Zika Test PID00000372 Nucleic acid test for use on the cobas® 5800/6800/8800 systems 09 040 676 190 9 040 676 190 09040676190 9040676190 09040676190 KIT COBAS 58/68/8800 ZIKA 480T IVD KIT COBAS 58/68/8800 ZIKA 480T IVD 00875197006568 Reagents, kits 480 tests Not Available true The cobas® Zika test for use on the cobas® 6800 and cobas® 8800 Systems is a qualitative in vitro nucleic acid screening test for the direct detection of Zika virus RNA in human plasma.This test is intended for use to screen donor samples for Zika virus RNA in plasma samples from individual human donors, including donors of whole blood and blood components, and other living donors. This test is also intended for use to screen organ and tissue donors when donor samples are obtained while the donor’s heart is still beating.Plasma from all donors may be screened as individual samples. For donations of whole blood and blood components, plasma samples may be tested individually or in pools comprised of not more than six individual samples.The test is not intended for use as an a id in diagnosis of Zika virus infection.This test is not intended for use on samples of other body fluids.This test is not intended for use on samples of cord blood. en cobas® Zika is based on fully automated sample preparation (nucleic acid extraction and purification) followed by PCR amplification and detection. The cobas® 6800/8800 Systems consist of the sample supply module, the transfer module, the processing module, and the analytic module. Automated data management is performed by the cobas® 6800/8800 software which assigns test results for all tests as non-reactive, reactive, or invalid. Results can be reviewed directly on the system screen, and printed as a report.Samples should be tested as individual samples or, optionally, can be tested in pools consisting of multiple samples. The cobas® Synergy software with the Hamilton MICROLAB® STAR IVD, may optionally be used in a pre-analytical step if pooling is to be performed.Nucleic acids from the sample and added armored RNA internal control (IC) molecules (which serve as the sample preparation and amplification/detection process control) are simultaneously extracted. In addition the test utilizes two external controls: a positive and a negative control. Viral nucleic acids are released by addition of proteinase and lysis reagent to the sample. The released nucleic acids bind to the silica surface of the added magnetic glass particles. Unbound substances and impurities, such as denatured proteins, cellular debris, and potential PCR inhibitors (such as hemoglobin) are removed with subsequent wash reagent steps and purified nucleic acids are eluted from the glass particles with elution buffer at elevated temperature.Selective amplification of target nucleic acid from the donor sample is achieved by the use of virus-specific forward and reverse primers which are selected from highly conserved regions of the viral nucleic acid. A thermostable DNA polymerase enzyme is used for both reverse-transcription and amplification. The master mix includes deoxyuridine triphosphate (dUTP), instead of deoxythimidine triphosphate (dTTP), which is incorporated into the newly synthesized DNA (amplicon). 26-28 Any contaminating amplicons from previous PCR runs are destroyed by the AmpErase enzyme [uracil-N-glycosylase], which is included in the PCR mix, when heated in the first thermal cycling step. However, newly formed amplicons are not destroyed since the AmpErase enzyme is inactivated once exposed to temperatures above 55°C.The cobas® Zika master mix contains detection probes which are specific for Zika virus and IC nucleic acid. The specific Zika virus and IC detection probes are each labeled with one of two unique fluorescent dyes which acts as a reporter. Each probe also has a second dye which acts as a quencher. The two reporter dyes are measured at defined wavelengths, thus permitting detection and discrimination of the amplified Zika virus target and the IC. 29, 30 When not bound to the target sequence, the fluorescent signal of the intact probes is suppressed by the quencher dye. During the PCR amplification step, hybridization of the probes to the specific single-stranded DNA template results in cleavage by the 5' to 3' nuclease activity of the DNA polymerase resulting in separation of the reporter and quencher dyes and the generation of a fluorescent signal. With each PCR cycle, increasing amounts of cleaved probes are generated and the cumulative signal of the reporter dye is concomitantly increased. Since the two specific reporter dyes are measured at defined wavelengths, simultaneous detection and discrimination of the amplified Zika target and the IC are possible.26. Longo MC, Berninger MS, Hartley JL. Use of uracil DNA glycosylase to control carry-over contamination in polymerase chain reactions. Gene. 1990; 93:125-8.27. Savva R, McAuley-Hecht K, Brown T, Pearl L. The structural basis of specific base-excision repair by uracil-DNA glycosylase. Nature. 1995; 373:487-93.28. Mol CD, Arvai AS, Slupphaug G, et al. Crystal structure and mutational analysis of human uracil-DNA glycosylase: structural basis for specificity and catalysis. Cell. 1995;80:869-78.29. Higuchi R, Dollinger G, Walsh PS, Griffith R. Simultaneous amplification and detection of specific DNA sequences. Biotechnology (NY). 1992;10:413-417.30. Heid CA, Stevens J, Livak JK, Williams PM. Real time quantitative PCR. Genome Res. 1996;6:986-994 en

User profile

Select your user profile

cobas^® Zika Test

Overview

Ordering information

Technical documents

Compatible products

Contact us